AMF | Jotup

SCOR announces the publication of its 2023 Universal Registration Document

Retrieved on:

Mercredi, mars 20, 2024

SCOR’s 2023 Universal Registration Document (“Document d’enregistrement universel”) established in ESEF format (European Single Electronic Format) was filed with the French financial market authority, the Autorité des marchés financiers (AMF), on March 20, 2024, under number D.24-0142.

Key Points:

SCOR’s 2023 Universal Registration Document (“Document d’enregistrement universel”) established in ESEF format (European Single Electronic Format) was filed with the French financial market authority, the Autorité des marchés financiers (AMF), on March 20, 2024, under number D.24-0142.
This document is available on SCOR’s website www.scor.com and the AMF website www.amf-france.org .
Hard copies of the document are also available at SCOR’s headquarters, located at the following address:
The Universal Registration Document includes the following information:
the 2023 annual financial report;
the report of the board of directors on corporate governance; and
the description of the share buyback program.
The Group generated premiums of EUR 19.4 billion in 2023 and serves clients in around 160 countries from its 35 offices worldwide.

Vallourec continues to implement its strategic plan with the arrival of ArcelorMittal, new reference shareholder

Retrieved on:

Mardi, mars 12, 2024

ArcelorMittal, Growth, Communication, Acquisition, Nature, AMF, Mining

This marks the final step of the financial restructuring of Vallourec that was initiated in 2021, when Apollo became Vallourec’s reference shareholder.

Key Points:

This marks the final step of the financial restructuring of Vallourec that was initiated in 2021, when Apollo became Vallourec’s reference shareholder.
Vallourec welcomes the transition in reference shareholder from Apollo, the leader of Vallourec’s successful financial restructuring, to ArcelorMittal, a global steel industry player.
It also represents a long-term commitment, as ArcelorMittal shares with Vallourec a common industrial vision and complementary, world-renowned expertise.
This transaction was made possible by the New Vallourec plan, which was announced in May 2022 with the arrival of Philippe Guillemot as CEO.

2023 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE 2023 ANNUAL FINANCIAL REPORT MADE AVAILABLE

Retrieved on:

Mardi, mars 12, 2024

AMF, Share repurchase, Audit

Rexel’s 2023 Universal Registration Document, including the annual financial report for the 2023 financial year, was filed on March 11, 2024 with the French Autorité des marchés financiers (AMF), under number D.24-0096.

Key Points:

Rexel’s 2023 Universal Registration Document, including the annual financial report for the 2023 financial year, was filed on March 11, 2024 with the French Autorité des marchés financiers (AMF), under number D.24-0096.
The Universal Registration Document notably includes the following information:
- The description of the share repurchase program;
- The statement of non-financial performance; and
- The reports of statutory auditors and information regarding their fees.
The Universal Registration Document is available on Rexel’s corporate website (www.rexel.com/en) in the “Investors – Regulated Information” section and on the AMF’s website (www.amf-france.org).
It is also available at no cost at Rexel’s headquarters, 13, boulevard du Fort de Vaux, 75017 Paris, France.

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on:

Jeudi, avril 4, 2024

Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points:

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

GLAS Completes Its Acquisition of French Fiducie and Asset Management Firm, Pristine

Retrieved on:

Mardi, avril 2, 2024

Banking, Asset Management, Professional Services, Finance, ACPR, Culture, Pierre & Vacances, Partnership, Acquisition, Avenue George V, GLAS, AMF, SMCP, Borosilicate glass

Global Loan Agency Services Limited (part of the global GLAS Group) is thrilled to announce the successful completion of its acquisition of Pristine.

Key Points:

Global Loan Agency Services Limited (part of the global GLAS Group) is thrilled to announce the successful completion of its acquisition of Pristine.
Pristine is a leading fiducie and asset management business.
The GLAS Group launched its French operations in Paris in 2018 and has since built out a sizeable team led by Aymeric Mahe, Head of GLAS SAS.
Since the original announcement of the proposal to acquire Pristine, GLAS have also, subject to regulatory approval, committed to partnering with Singaporean-based Watiga.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on:

Vendredi, mars 22, 2024

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points:

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.

Sensorion Announces the Availability of its Financial Report for 2023

Retrieved on:

Jeudi, mars 14, 2024

Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AMF, Bank statement, Financial statement

Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announces that it is today publishing its Full Year 2023 Financial Report, which has been filed with the Autorité des marchés financiers (AMF).

Key Points:

Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announces that it is today publishing its Full Year 2023 Financial Report, which has been filed with the Autorité des marchés financiers (AMF).
The Financial Report for 2023 includes:
The Annual Accounts and the Financial Statements; and
The information on fees paid to the Statutory Auditors of the 2023 accounts.
The Annual Financial Report is being made available on the following websites:
It is also available to the public, free of charge and on request:
At the Company's headquarters: 375 rue du Professeur Joseph Blayac - 34080 Montpellier, France.

Ellevio announces a cash offer of SEK 90 per share to the shareholders of Dala Energi

Retrieved on:

Mardi, avril 2, 2024

STOCKHOLM, April 2, 2024 /PRNewswire/ -- The Ellevio group, through Ellevio Holding 1 AB[1] ("Ellevio") together with its subsidiaries (the "Ellevio Group"), hereby announces a public offer to the shareholders of Dala Energi AB (publ)[2] ("Dala Energi" or the "Company") to tender all shares in Dala Energi to Ellevio at a price of SEK 90 per share (the "Offer"), which represents a premium of 86.5 per cent to the volume-weighted average trading price of SEK 48.3 for the shares over the last 90 trading days. The shares in Dala Energi are listed on Nasdaq First North Growth Market.

Key Points:

Ellevio offers SEK 90 in cash per share (the "Offer Price") in Dala Energi.
The total value of the Offer, based on all 24,771,656 shares in Dala Energi amounts to approximately SEK 2,229 million.
Ellevio offers SEK 90 in cash for each share in Dala Energi.
Dala Energi is the parent company in a group with the fully owned subsidiaries Dala Energi Kraftproduktion AB, Dala Energi Fibernät AB and Dala Energi Elnät AB.

Ellevio announces a cash offer of SEK 90 per share to the shareholders of Dala Energi

Retrieved on:

Mardi, avril 2, 2024

STOCKHOLM , April 2, 2024 /PRNewswire/ -- The Ellevio group, through Ellevio Holding 1 AB[1] ("Ellevio") together with its subsidiaries (the "Ellevio Group"), hereby announces a public offer to the shareholders of Dala Energi AB (publ)[2] ("Dala Energi" or the "Company") to tender all shares in Dala Energi to Ellevio at a price of SEK 90 per share (the "Offer"), which represents a premium of 86.5 per cent to the volume-weighted average trading price of SEK 48.3 for the shares over the last 90 trading days. The shares in Dala Energi are listed on Nasdaq First North Growth Market.

Key Points:

Ellevio offers SEK 90 in cash per share (the "Offer Price") in Dala Energi.
The total value of the Offer, based on all 24,771,656 shares in Dala Energi amounts to approximately SEK 2,229 million.
Ellevio offers SEK 90 in cash for each share in Dala Energi.
Dala Energi is the parent company in a group with the fully owned subsidiaries Dala Energi Kraftproduktion AB, Dala Energi Fibernät AB and Dala Energi Elnät AB.

Annual General Meeting of AB Volvo

Retrieved on:

Mercredi, mars 27, 2024

Annual, EUR, Volvo, Exercise, AB, AFA, Stockholm Concert Hall, Audit committee, Meeting, Annual general meeting, AMF, Election Committee (Hong Kong), Nasdaq Stockholm

GOTHENBURG, Sweden, March 27, 2024 /PRNewswire/ -- The Annual General Meeting adopted the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. In accordance with the Board's proposal, the Meeting resolved that an ordinary dividend of SEK 7.50 per share and an extraordinary dividend of SEK 10.50 per share should be paid to the shareholders. April 2, 2024 was decided as the record date for the right to receive dividends.

Key Points:

AB Volvo held its Annual General Meeting on March 27, 2024.
GOTHENBURG, Sweden, March 27, 2024 /PRNewswire/ -- The Annual General Meeting adopted the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet.
The auditing firm Deloitte AB was re-elected as Auditor for the period until the close of the Annual General Meeting 2025, in accordance with the Election Committee's proposal and the Board's and the Audit Committee's recommendation.
The Annual General Meeting approved the Board's remuneration report.